Pfizer To Put Big Marketing Muscle Behind Migraine With Biohaven Purchase

 
• By Jessica Merrill
  
Generate a summary of this article
Listen to this article
Beta

Pfizer’s $11.6bn acquisition of the company brings it full rights to the oral migraine drug Nurtec ODT and nasal spray zevegepant, with aims to build a $6bn migraine franchise.

muscle
Pfizer plans to put big marketing muscle behind Nurtec • Source: Shutterstock

Pfizer Inc. is poised to enter the migraine market with the full strength of its marketing power, raising the stakes in an already crowded and competitive commercial market. Pfizer announced a deal on 10 May to buy the migraine specialist Biohaven Pharmaceutical Holding Company Ltd. in a transaction valued at $11.6bn, gaining the oral migraine drug Nurtec ODT (rimegepant) and a nasal spray, zavegepant, pending at the US Food and Drug Administration, as well as five preclinical calcitonin gene-related peptide (CGRP) inhibitor assets.

The deal fulfills Pfizer's promise to investors to expand its late-stage and commercial portfolio with near-term growth drivers and puts...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.